Index Entries

Jérémie Botton, Marion Bertrand, Marie-Joëlle Jabagi, Lise Duranteau, Kim Bouillon, Jérôme Drouin, Laura Semenzato, Stéphane Le Vu, Alain Weill, Mahmoud Zureik, and Rosemary Dray-Spira
September 2, 2024
Vaccine
EPIPHARE Scientific Interest Group in Epidemiology of Health Products (France)

"Abstract

Background: COVID-19 vaccination has been inconsistently associated with an increased risk of heavy menstrual bleeding in previous studies. This study aimed to assess the risk of heavy menstrual bleeding requiring hospital care following COVID-19 vaccination according to the number of doses received and the time elapsed since vaccination.

Methods: Using comprehensive data of the French National Health Data System, we carried out a case-control study. ...

Results: A total of 4610 cases and 89,375 matched controls were included (median age, 42 years). Compared to unvaccinated women, the risk of hospital care for heavy menstrual bleeding was increased in those having received a last dose of primary vaccination in the preceding 1–3 months (Odds Ratio, 1.20 [95% confidence interval, 1.07–1.35]). This association was marked among women residing in the most deprived municipalities (1.28 [1.07–1.52]) and those who were not using hormonal contraception (1.28 [1.11–1.48]). Assuming a causal relationship, a total of 103 cases [54–196] were estimated to be attributable to primary vaccination in France.

Conclusion: These findings provide evidence of an increased risk of heavy menstrual bleeding during the three-month period following primary COVID-19 mRNA vaccination."

document
adverse events,COVID-19,reproductive system issues,vaccines